Evidence map›Paper›PMID 19034017›Full record

ArticleTransplantation2008

Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses.

Yih-Jyh Lin, Hidetaka Hara, Hao-Chih Tai, Cassandra Long, Daisuke Tokita, Peter Yeh, David Ayares, Adrian E Morelli, David K C Cooper

Abstract read
In one paragraph

Article in Transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Genetically engineered porcine liver: a new era in transplantation.International journal of surgery (London, England) · 2026
    Article
  2. Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Xenotransplantation: A New Era.Frontiers in immunology · 2022
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Skin xenotransplantation: Historical review and clinical potential.Burns : journal of the International Society for Burn Injuries · 2018
    Review
  12. Article
  13. Clinical Grade Regulatory CD4Frontiers in immunology · 2018
    Review
  14. Article
  15. Article
  16. Immunological challenges and therapies in xenotransplantation.Cold Spring Harbor perspectives in medicine · 2014
    Review
  17. Article
  18. Review
  19. Regulatory T-cell therapy in transplantation: moving to the clinic.Cold Spring Harbor perspectives in medicine · 2013
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yih-Jyh LinThomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA.
Hidetaka Hara
Hao-Chih Tai
Cassandra Long
Daisuke Tokita
Peter Yeh
David Ayares
Adrian E Morelli
David K C Cooper

Funding

Thromboregulation to Prevent Thrombotic MicroangiopathyU01AI068642 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2005 to 2008
$2.7M
NIAID NIH HHS U01 AI068642NIAID NIH HHS U01-AI068642
6 · The paper itself

Abstract

backgroundAn understanding of the mechanisms that suppress the human anti-pig cellular response is key for xenotransplantation. We have compared the ability of human regulatory T cells (Tregs) to suppress xenogeneic and allogeneic responses in vitro.

methodsHuman peripheral blood mononuclear cells (PBMC), CD4+ T cells, or CD4+ CD25- T cells were stimulated with irradiated human or wild type (WT) or alpha1,3-galactosyltransferase gene-knockout (GT-KO) pig PBMC in the presence or absence of human CD4+ CD25 high Tregs. In separate experiments, 5- (and 6)-carboxyfluorescein diacetate succinimidyl ester-labeled human CD4+ T cells were stimulated with human or pig PBMC. The expansion and precursor frequencies of allo- and xenoreactive Tregs were assessed by labeling with FoxP3 mAb and flow cytometric analysis.

resultsThe responses of human PBMC, CD4+ T cells, and CD4+ CD25- T cells to pig PBMC were stronger than to human PBMC (P<0.05). Human anti-GT-KO responses were weaker than anti-WT responses (P<0.05). Human CD4+ CD25 high Tregs suppressed proliferation of CD4+ CD25- T cells to both human and pig PBMC stimulator cells with the same efficiency. Alloreactive CD4+ CD25+ FoxP3 high responder T cells proliferated more than their xenoreactive counterparts (P<0.05), although xenoreactive CD4+ CD25+ T cells proliferated more than alloreactive cells (P<0.05). There was no difference in precursor frequency between allo- and xeno-reactive CD4+ CD25+ FoxP3 high cells.

conclusionsHuman T-cell responses to pig cells are stronger than to allogeneic cells. The human response to GT-KO PBMC is weaker than to WT PBMC. Although human Tregs can suppress both responses, expansion of CD4+ CD25+ FoxP3 high cells against pig PBMC is weaker than against human PBMC. More human Tregs may be required to suppress the stronger xenogeneic response.

Indexed as

AnimalsAnimals, Genetically ModifiedAntigens, CDCD4-Positive T-LymphocytesGalactosyltransferasesGraft RejectionHumansImmunosuppression TherapyInterleukin-2 Receptor alpha SubunitSwineT-Lymphocytes, RegulatoryTransplantation, HeterologousTransplantation, HomologousAntigens, CDGalactosyltransferasesInterleukin-2 Receptor alpha Subunit

Identifiers

PMID19034017
PMCPMC2629735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.